Trastuzumab exposure in early pregnancy for a young lady with locally invasive breast cancer

Abstract

The available literature on the effects of trastuzumab on pregnancy in the first trimester is limited. Case reports discuss the presence of oligohydramnios on fetal USS that result in a living baby that seemingly lacks any abnormalities. There may also be a link with higher rates of spontaneous abortion. We describe a young 32 year old on trastuzumab for a locally invasive HER2-positive breast cancer who became pregnant with fetal exposure to the treatment. After cessation of trastuzumab at 28 weeks, she delivered a healthy baby girl at 37 weeks gestation who, at 7 years of age now, still does not display any evidence of negative effects of trastuzumab exposure.

Pregnancy Outcome from an Oocyte Retrieval Following Chemotherapy for Breast Cancer

“…Little is known about newer monoclonal antibody agents that the patient in case 2 received regarding their effects on the ovary and fertility. Most of the data on these agents comes from limited case reports of women who incidentally became pregnant while on adjuvant treatment with these agents and outcomes report healthy term infants as well as some cases of oligohydramnios [21].…”